

### **SUMMARY OF CLAIMS**

Claims 1-25 and 45-53 are withdrawn. Claims 26-44 are pending. Reconsideration is respectfully requested in light of the following remarks.

### **RESPONSE TO RESTRICTION REQUIREMENT**

The Examiner has identified the following ten claimed inventions and has required the Applicants to restrict the application under 35 U.S.C. 121 and 372:

Group I, claim(s) 1-25 and 49, drawn to a method for identifying a drug discovery target.

Group II, claim(s) 26-44, drawn to a method for evaluating user-supplied genomics data using a structured database that permits the computations of complex relationships.

Group III, claim(s) 45, drawn to a method for identifying a new use for a known therapy comprising the steps of providing a means for storing and accessing genomics information.

Group IV, claim(s) 46, drawn to a method for prioritizing candidate development compounds.

Group V, claim(s) 47, drawn to a method for identifying disease-related pathways.

Group VI, claim(s) 48, drawn to a method for identifying and validating a genotypic marker for a disease state.

Group VII, claim(s) 50, drawn to a method of conducting business that comprises receiving compensation from a customer.

Group VIII, claim(s) 51, drawn to a drug discovery target.

Group IX, claim(s) 52, drawn to a method of drug discovery

Group X, claim(s) 53, drawn to a drug candidate.

Applicants elect Group II without traverse. Claims 26-44 encompass the elected invention. Applicants reserve the right pursuant to 35 U.S.C. §121 to file one or more divisional applications directed to the non-elected invention during the pendency of the present application.

Examiner also advised the Applicants to (i) elect a species of invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identify the claims encompassing the elected invention.

The Applicants elect “gene” as the species of the invention to be examined without traverse. The species “gene” reads on claims 26-44.

**CONCLUSION**


In light of the remarks set forth above, Applicants believe that they are entitled to letters patent. Applicants respectfully solicit the Examiner to expedite the prosecution of this patent application to issuance. Should the Examiner have any question, the Examiner is encouraged to telephone the undersigned.

The Commissioner is authorized to charge any underpayment or credit any overpayment to Deposit account No. 23-2415 (Attorney Docket No. 27763-705.831) for any matter in connection with this response, including any fee for extension of time, which may be required.

Respectfully submitted,

WILSON SONSINI GOODRICH & ROSATI

Dated: February 18, 2009

By:   
Paul Borchardt, Reg. No. 53,999

650 Page Mill Road  
Palo Alto, CA 94304-1050  
(650) 493-9300  
Customer No. 021971